Gemcitabine (Gemzar(R)) is an effective chemotherapeutic drug approved for treatment of several cancers, including non-small cell lung cancer (NSCLC), pancreatic, breast and ovarian cancer. However, its use has been limited due to its short half-life and significant systemic toxicity. This proposal utilizes a novel Lipid-Calcium-Phosphate (LCP) nanoparticle platform for the design of multifunctional targeted nanoparticles (NP) to deliver gemcitabine triphosphate (GTP) and 111Indium to cancer cells. In these novel particles GTP is a therapeutic agent and 111Indium is a radio-imaging agent. These resulting LCP-GTP-Indium theranostic nanoparticles will be evaluated for efficacy in lung tumor models and imaging capabilities. The novel NPs will also be evaluated for preliminary toxicity in normal mice. The targeted LCP-GTP-Indium theranostic nanoparticles are expected to increase the half-fife and lower the toxicity of gemcitabine while simultaneously allowing for tumor imaging capabilities. Development of GTP+lndium nanoparticles will improve the delivery of a known chemotherapy drug and enhance the potential for expanded use of this drug in lung and other cancers. Furthermore 111Indium will allow in vivo tracking and imaging of NP without affecting the NP characteristics or biodistribution. This diagnostic capability will enable individualized treatment based on biodistribution, leading to a true personalized medicine product.

Agency
National Institute of Health (NIH)
Type
Small Business Innovation Research – Phase I (N43)
Project #
261201100054C-2-0-1
Application #
8429089
Study Section
Project Start
2011-09-27
Project End
2012-08-27
Budget Start
Budget End
Support Year
Fiscal Year
2012
Total Cost
$179,834
Indirect Cost
Name
Qualiber, Inc.
Department
Type
DUNS #
962735374
City
Chapel Hill
State
NC
Country
United States
Zip Code
27514